Alexandre Vivot

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015

Alexandre Vivot, Justine Jacot, Jean‐David Zeitoun et al. · Annals of Oncology · 2017 · 132 citations · Full text

Preclinical Therapeutics, Medicine, Cancer Management +12

Jump, Hop, or Skip: Modeling Practice Effects in Studies of Determinants of Cognitive Change in Older Adults

Alexandre Vivot, Melinda C. Power, M. Maria Glymour et al. · American Journal of Epidemiology · 2016 · 123 citations · Full text

Using an Alzheimer Disease Polygenic Risk Score to Predict Memory Decline in Black and White Americans Over 14 Years of Follow-up

Jessica R. Marden, Elizabeth Rose Mayeda, Stefan Walter et al. · Alzheimer Disease & Associated Disorders · 2016 · 83 citations · Full text

Geriatric Psychiatry, Aging, Genetic Epidemiology +24

Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004–2012

Philippe Morlat, Alexandre Vivot, M.A. Vandenhende et al. · PLoS ONE · 2013 · 59 citations · Full text

Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus

M. Geneviève, Alexandre Vivot, C. González et al. · Diabetes & Metabolism · 2013 · 57 citations

Type 1, Diabetes Management, Skin Autofluorescence +7